治疗模式

Antibodies are our immune system's natural defense against disease. Monoclonal antibodies are similar proteins created in the lab and designed to bind to a specific disease-causing protein selectively. They originate from a single clone that can make identical copies of the same antibody in large amounts.
\r\n
\r\nWith extensive experience discovering and developing monoclonal antibodies, we're uncovering new insights to help inform treatments in various therapeutic areas, including immunology, oncology and neurology.

\r\n"}}" id="text-a9e90991e9" class="cmp-text">

我们的免疫系统抗体的自然防御疾病。单克隆抗体是相似的蛋白质实验室,设计中创建绑定到一个特定的致病蛋白质选择性。他们来自一个克隆,可以使相同的抗体大量一模一样的复制品。

用单克隆抗体的勘探和开发的丰富经验,我们发现新见解帮助治疗各治疗领域,包括免疫学、肿瘤学与神经学方面。

Multispecific antibodies are engineered in the laboratory and can bind multiple targets or sites simultaneously. This ability to bind to multiple targets distinguishes them from monoclonal antibodies and allows the disease to be attacked in novel ways.
\r\n
\r\nFirst-generation bispecific antibodies have demonstrated efficacy in certain blood cancers, but their effect on solid tumors has been limited. We see significant promise in bispecific antibodies and are investigating a T-cell-redirected bispecific platform to target hematologic and solid tumors.
\r\n

\r\n"}}" id="text-5463393ed8" class="cmp-text">

Multispecific抗体工程在实验室和可以同时绑定多个目标或网站。这种绑定到多个目标的能力区分他们从单克隆抗体,并允许在小说方面疾病的攻击。

第一代双特异性抗体已经证明了在某些血液癌症的功效,但其对实体肿瘤的影响是有限的。我们看到双特异性抗体的重要承诺,正在调查T-cell-redirected双特异性平台目标血液和实体肿瘤。

Antibody-drug conjugates (ADCs) are designed to deliver a drug directly to where it's needed by a targeting antibody. They're comprised of monoclonal antibodies linked to a small molecule drug and used in cancer to selectively kill tumor cells.
\r\n
\r\nWe are actively exploring the use of ADCs in immunology. We're developing a novel ADC platform for immune-mediated diseases and expanding this technology's scope by exploring next-generation ADCs in oncology.

\r\n"}}" id="text-437ce162bf" class="cmp-text">

抗体药物配合(adc)旨在提供一种药物直接针对抗体所需要的。他们组成的单克隆抗体与小分子药物和用于癌症选择性杀死肿瘤细胞。

我们积极探索利用adc免疫学。我们开发一种新颖的免疫介导性疾病和ADC平台扩大该技术的探索下一代ADC的肿瘤范围。

"Degradomers" are molecules that degrade proteins through the power of targeted protein degradation. We're developing degradomers that are designed to hijack the body's natural system of protein degradation to help eliminate disease-causing proteins.
\r\n
\r\nAbbVie researchers are exploring how to utilize degradomers to go after disease targets that have been traditionally considered undruggable in areas such as oncology, immunology and neurology.

\r\n"}}" id="text-3982a9fa1e" class="cmp-text">

“Degradomers”分子降解蛋白质通过有针对性的蛋白质降解的力量。我们正在开发设计的degradomers劫持人体的自然系统的蛋白质降解来帮助消除致病蛋白质。

AbbVie研究人员正在探索如何利用degradomers去无药可治疾病目标后,传统上认为在肿瘤等领域,免疫学和神经学。

Gene therapy uses viral vectors to deliver genetic material to disease tissue that can modify or replace a faulty gene with a functional one or produce therapeutic proteins directly inside the diseased tissue in the patient.
\r\n
\r\nWe are working to develop next-generation gene therapies for patients in need and whose conditions could potentially benefit from this approach. In eye care, we are using gene therapy to help improve the treatment of retinal diseases such as wet AMD, which currently involves frequent injections into patients' eyes

\r\n"}}" id="text-02bfe23534" class="cmp-text">

基因疗法使用病毒载体传递遗传物质疾病组织可以修改或替换有缺陷的基因与一个或产生治疗性蛋白质功能直接在病人的病变组织。

我们正在开发新一代基因疗法的病人需要和条件可能会受益于这种方法。在眼部护理,我们利用基因疗法来帮助改善湿性AMD等视网膜疾病的治疗,目前需要频繁注射到病人的眼睛

Cell therapy uses living genetically modified immune cells to treat disease. The cells which are infused into the patient can either be from that patient (autologous) or a donor (allogeneic) and, hopefully in the future, derived from induced pluripotent stem cells (iPSC).
\r\n
\r\nOne example of this approach is chimeric antigen receptor T-cell (CAR-T) therapy. In CAR-T therapy, T cells (a type of immune cell) from a patient or donor are engineered to target molecules on the surface of cancer cells to kill them. Novel approaches investigate ways to engineer T cells in situ and venture into new immune cell populations, such as natural killer (NK) cells and macrophages.
\r\n
\r\nWe invest in advanced gene editing and precision medicine technologies to develop next-generation autologous and allogeneic CAR-T therapies to treat solid tumors and heme malignancies.

\r\n"}}" id="text-f92fb27625" class="cmp-text">

细胞疗法使用转基因的免疫细胞治疗疾病。细胞被注入到患者可以从病人(自体)或捐赠(同种异体),希望在未来,来自诱导多能干细胞(iPSC)。

这种方法的一个例子是嵌合抗原受体t细胞(CAR-T)治疗。CAR-T治疗T细胞(一种免疫细胞)从病人或捐赠设计目标分子表面的癌细胞杀死他们。新方法调查方法工程师T细胞原位和进入新的免疫细胞的数量,如自然杀伤(NK)细胞和巨噬细胞。

我们投资于先进的基因编辑和精密医学技术发展下一代自体和同种异体CAR-T疗法治疗实体肿瘤和血红素的恶性肿瘤。

Small molecules are the most traditional pharmaceuticals. They are relatively simple in structure and can be chemically synthesized. Because of their small size, they can often be administered orally and easily enter cells. Once inside cells, they can interact with target molecules like enzymes and proteins to help regulate biological processes to treat disease.
\r\n
\r\nWith our deep experience in small molecule chemistry, we are committed to new thinking and approaches that can make a greater impact on the treatment of disease. We are developing novel small molecule therapies across all therapeutic areas.

\r\n"}}" id="text-dc7c659978" class="cmp-text">

小分子是最传统的药品。它们在结构上相对简单,可以化学合成。因为他们的体积小,他们通常可以口服药物,容易进入细胞。一旦进入细胞,它们可以与目标分子如酶和蛋白质帮助调节生物过程来治疗疾病。

在小分子化学与我们深度经验,我们致力于新思路和方法,可以产生更大的影响对疾病的治疗。我们正在开发新型小分子疗法在所有治疗领域。